Newly Developed Effective Anti-Cancer Drugs Targeting Multiple Myeloma

Daniel Man-Yuen Sze,Jian Hou,Lily Zhou

DOI: https://doi.org/10.1002/ddr.20275

2008-01-01

Drug Development Research

Abstract:Multiple myeloma (MM) is considered predominantly a cancer of the elderly with a median patient age of 60-65 years at diagnosis and 88% of patients being over 55 years. The disease has remained incurable with a mean survival period of about 3 years for the last 30 years. In the last decade, three useful cancer drugs, namely, thalidomide, lenalidomide, and bortezomib, have been approved by the FDA to append the armamentarium of MM chemotherapy other than the standard combination of melphalan and prednisone that have been used since the 1960s. Many clinical trials supported by in vitro laboratory investigations have been conducted to understand both the efficacy and mechanisms of the action of these cancer drugs. This brief review aims to provide an overview of new cancer drugs targeting MM and discuss the development of novel strategies for targeting this incurable disease. Drug Dev Res 69 : 451-459,2008. (c) 2008 Wiley-Liss, Inc.